Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.

Douxfils, J;Dogné, J-M;Mullier, François;Chatelain, Bernard;Hjemdahl, P;et.al.
(2013) Thrombosis and Haemostasis : international journal for vascular biology and medicine — Vol. 110, n° 3, p. 543-549 (2013)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 563.95 KB
Request a copy

Details

Authors
  • Douxfils, J
    Author
  • Dogné, J-M
    Author
  • Mullier, FrançoisUCLouvain
    Author
  • Chatelain, BernardUCLouvain
    Author
  • Hjemdahl, P
    Author
Show more
Abstract
Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations. Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been proposed to evaluate dabigatran concentrations, but previous findings are based on in vitro studies and results must be confirmed in clinical samples. It was the aim of this study to compare aPTT and HTI measurements with liquid chromatography-tandem mass spectrometry (LC-MS/MS) measurements of dabigatran in plasma samples from DE treated patients. Seventy-one plasma samples were included. aPTT was performed using STA-CKPrest® and SynthASil®. HTI was performed according to instructions from the manufacturer. The LC-MS/MS method utilised dabigatran-d3 as internal standard. The plasma concentration range was 0 to 645 ng/ml as measured by LC-MS/MS. Overall, the HTI and LC-MS/MS analyses correlated well (r²=0.97). The Bland-Altman analysis showed a mean difference of 9 ng/ml (SD: 20 ng/ml). However, the HTI performed poorly at concentrations <50 ng/ml. LC-MS/MS was sensitive (limit of quantification 1.1 ng/ml) and specific for dabigatran. The aPTT methods did not correlate well with plasma concentrations measured by LC-MS/MS (r² = 0.59 with SynthASil® and 0.50 with STA-CKPrest®). In conclusion, the poor sensitivity, important inter-individual variability, and poor correlation with LC-MS/MS preclude the use of aPTT to estimate dabigatran concentrations. Due to its small inter-individual variability and good agreement with LC-MS/MS measurements, we recommend the use of HTI assays to rather accurately estimate concentrations of dabigatran >50 ng/ml. Quantification of lower dabigatran levels in DE-treated patients requires the "reference" LC-MS/MS method.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Douxfils, J., Dogné, J.-M., Mullier, F., Chatelain, B., Rönquist-Nii, Y., Malmström, R. E., & Hjemdahl, P. (2013). Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis : international journal for vascular biology and medicine, 110(3), 543-549. https://doi.org/10.1160/TH13-03-0202 (Original work published 2013)